The leading source of information about the medicinal cannabis industry in Australia
The team at FreshLeaf Analytics are experts in the medicinal cannabis market in Australia.
FreshLeaf has sized markets, assessed patient populations, evaluated formations and delivery mechanisms, managed patient trials, supported the drafting of regulations and driven key industry decisions with regulators. FreshLeaf also has exclusive access to significant datasets generated by some of Australia’s largest medicinal cannabis healthcare companies.
We use our expertise, knowledge and exclusive data access to answer real-world questions from our clients such as Where is the opportunity for new product market entry? Will my price point be competitive? How much do patients pay per month? What is the average dosage? What market sectors are growing fastest?
Our team of consultants and statisticians can help you understand the Australian medicinal cannabis market, where the opportunities are and what should be avoided. Our team undertakes a range of projects from strategic consulting engagements to ongoing monthly structured data reporting.
FreshLeaf Analytics has exclusive access to medicinal cannabis product and clinical data sets from some of Australia’s leading healthcare companies. We combine this data with information from regulators to generate unique insight into the state of the medicinal cannabis market in Australia.
FreshLeaf has access to full product details for most medicinal cannabis products available in the marketplace in Australia.
FreshLeaf collaborates with key pharmacy partners to provide insights on wholesale and retail data
FreshLeaf has access to the single largest patient dataset in the country, covering information about conditions, prescripts, dosages, and patient outcomes
FreshLeaf has access to product pricing, and patient spending by condition
Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product
FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020 Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter
TGA Defers Decision to Pay for Epidyolex The Pharmaceutical Benefits Advisory Committee (PBAC), the body that decides whether Australians can have certain medicines subsidised by
© 2020 All rights reserved, FreshLeaf Analytics
